Vaxin Inc., a promising biotech company spun from research at the University of Alabama at Birmingham, quietly moved from Innovation Depot to a new home in Maryland as it continues development of vaccines for the flu and anthrax.
The company, founded in 1997, has consolidated its staff and lab space on the East Coast in order to be closer to funding and a number of other vaccine development companies, Chief Executive Bill Enright said Thursday. He said other reasons for the move were to consolidate costs and get closer to the company’s primary source of funding, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Developm
{iframe}http://blog.al.com/businessnews/2012/07/vaxin_moves_from_birmingham_to.html{/iframe}